Evorel is commonly used across therapeutic domains where additional symptomatic support is needed due to estrogen deficiency, helping to manage conditions presenting with systemic or localized discomfort.

---

What Evorel Treats: Main Uses and Benefits

Evorel is generally applied across conditions presenting with acute or disruptive symptom patterns, offering supportive relief that helps patients cope more steadily with difficult episodes. It is primarily considered relevant for easing symptoms related to vasomotor instability (such as hot flushes and night sweats), addressing urogenital atrophy (including vaginal dryness and irritation), and for skeletal preservation in postmenopausal women at high risk of fracture.

In clinical settings that involve acute or unstable symptom patterns, the therapy helps address symptom clusters that may become intense or disruptive. The therapy may assist with maintaining a sense of stability when symptoms are more noticeable. This focus on stabilization assists with maintaining functional stability, particularly concerning sleep quality and overall physical comfort.

Quick Fact	Focus of Therapeutic Support
Main Focus	Menopausal symptoms (e.g., hot flushes)
Additional Focus	Prevention of bone density loss (osteoporosis risk management)
Context of Use	Conditions presenting with systemic or localized discomfort

The use in these scenarios contributes to improved day-to-day comfort and supports general well-being during symptomatic phases.

Who Can and Cannot Use Evorel?

Eligibility for Evorel, a prescription Hormone Replacement Therapy (HRT), is strictly defined by regulatory documents, focusing primarily on the woman's postmenopausal status and medical history.

Populations Allowed and Contraindicated

Evorel is intended for use in postmenopausal women to treat oestrogen deficiency symptoms. Women who have an intact uterus must be eligible only if a progestogen is mandatory added to the regimen to prevent the risk of endometrial overgrowth.

Evorel is contraindicated (must not be used) in several absolute populations due to regulatory-defined risk. These include individuals with a history of or suspected Breast Cancer or other Estrogen-Dependent Malignant Tumours. Use is also prohibited for those with active or past Venous Thromboembolism (e.g., DVT, PE), Arterial Thromboembolic Disease (e.g., Stroke, MI), Active Liver Disease, Porphyria, or Undiagnosed Genital Bleeding.

Age and Status Restrictions

Status or Age Group	Regulatory Classification
Pregnancy and Lactation	Contraindicated; must be withdrawn immediately
Children and Adolescents	Not indicated for use
Women over 65 years	Experience is limited; data are insufficient

Conditional Use

Close supervision is required for eligibility in women with pre-existing conditions such as Hypertension, Leiomyoma (fibroids), Endometriosis, Diabetes Mellitus, or certain Liver/Renal Dysfunction.

Evorel, which contains estradiol, may interact with certain medicinal products, leading to a reduction in the plasma concentration and therapeutic effect of the estrogen component. This is primarily a pharmacokinetic interaction caused by the induction of liver enzymes.

Documented Interacting Medicines

Specific medicines and product classes are officially listed as having the potential to decrease the effectiveness of Evorel, potentially leading to signs like unscheduled bleeding. These include:

• Anticonvulsants (e.g., phenobarbital, phenytoin, carbamazepine).
• Anti-infectives used for tuberculosis (e.g., rifampicin, rifabutin).
• Antivirals for HIV/Hepatitis C (e.g., non-nucleoside reverse transcriptase inhibitors, protease inhibitors).
• Herbal remedies containing St John's Wort (Hypericum perforatum).

The interaction mechanism for these agents is generally classified as enzyme induction, where the concomitant medicine increases the rate at which estradiol is metabolized by the liver’s cytochrome P450 (CYP) isoenzymes.

As Evorel is a transdermal patch, it avoids the first-pass effect in the liver, meaning the impact of enzyme-inducing agents may be less pronounced compared to oral estrogen-only therapies. However, reduced efficacy remains a documented concern. Patients starting any of these interacting medicines or products while using Evorel should be aware of the potential for a change in treatment effectiveness.

Evorel's active component, estradiol, is chemically identical to the body's naturally occurring estrogen and exerts its function by binding to and activating specific estrogen receptors (ERs) within various tissues. This mechanism operates primarily through two domains, resulting in subsequent pathway-level physiological consequences.

---

Estrogen Receptor-Mediated Signaling

Estradiol acts as an agonist for both the ER-alpha and ER-beta receptors, which are found in diverse target cells. Binding initiates a change in the receptor conformation, allowing the hormone-receptor complex to translocate to the nucleus. This complex then binds to specific DNA sequences (Estrogen Response Elements), initiating a transcriptional cascade that modulates the expression of target genes and regulates the synthesis of various structural and regulatory proteins.

---

Modulation of Homeostatic Pathways

Through this receptor binding, estradiol engages mechanisms that influence cell activity in systems such as bone metabolism. Specifically, it modulates pathways involved in bone turnover, resulting in the suppression of osteoclast activity (bone resorption) and the promotion of osteoblast function (bone formation). This modification alters the overall cellular equilibrium within the skeletal structure, influencing bone density.

How Evorel is Used: Official Administration Guidelines

Evorel is prescribed with a specific protocol to ensure continuous delivery of estradiol via the transdermal route. The medicine is a matrix-type patch that is designed for systemic, through-the-skin absorption, circumventing the initial metabolic pass that occurs with oral medication.

Official Dosing and Frequency

Evorel must be applied and changed twice weekly (every three to four days) to maintain a consistent hormonal balance. Dosing typically starts at 50 mu g/24 hours, and the dose is adjusted to the lowest effective strength required for treatment, with a recommended maximum of 100 mu g/24 hours. The need for continued therapy should be periodically re-evaluated by a healthcare provider.

Administration Rule	Official Requirement
Route	Transdermal (through the skin)
Standard Start Dose	50 mu g/24 hours
Frequency	Twice weekly (every 3–4 days)

Application and Procedural Requirements

The patch must be applied to clean, dry skin on the trunk below the waistline (e.g., lower abdomen or buttocks). Crucially, the patch must not be placed on or near the breasts. The application sites must be rotated to prevent localized irritation, allowing a minimum of one week before reusing the same specific area.

For women who still have an intact uterus, the official use protocol mandates the co-administration of a progestogen for at least 12 to 14 days of every 28-day cycle. Evorel is not indicated for use in children.

Research Evidence / Overview of Studies for Evorel

---

Evidence for Relief of Vasomotor Symptoms (Hot Flushes and Night Sweats)

Research exploring outcomes related to transdermal estradiol patches, such as Evorel, primarily consists of short-term Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. These studies were used in research exploring how symptoms change over time, comparing the experience of women using the active patch against those using a placebo.

Studies monitored outcomes related to physical discomfort by tracking the daily frequency and perceived intensity of hot flushes and night sweats, along with changes in sleep quality. Research has explored short-term symptom changes, and studies reported patterns in the changes measured during this short period, generally within a follow-up period ranging from 4 to 12 weeks.

Evidence related to VMS was studied for postmenopausal women experiencing symptoms categorized as moderate to severe. However, follow-up durations were limited for long-term tracking of symptom control. Limited comparative evidence is also available from head-to-head RCTs that directly compare the transdermal patch against oral estrogen formulations in VMS research.

---

Evidence for Prevention of Bone Density Loss

Research explored skeletal health outcomes in postmenopausal women, with research focusing on conditions marked by functional limitations related to bone density. The evidence base includes RCTs—where bone health was frequently a long-term measure—and meta-analyses that synthesize data from multiple trials.

Research examined outcomes, specifically focusing on the change in Bone Mineral Density (BMD) at critical areas like the hip and spine. Longer studies explored and tracked fracture rates. Findings describe patterns observed in the studies, where trials spanning one to two years reported measurements related to BMD status in the observed populations.

Data for long-term outcomes, particularly those related to fracture rates, are still emerging and sometimes rely on pooling evidence from various HRT types, including oral administration; this means the evidence is not exclusively derived from the transdermal patch. Evidence is limited for women for whom other suitable first-line options for osteoporosis prevention are appropriate.

---

Comparative Evidence on Delivery Route

One distinct area of research involves comparing the delivery method—the transdermal patch—against the more traditional oral estrogen tablet. This research was evaluated in observational studies, such as large cohort studies, rather than in primary, controlled RCTs.

Studies explored outcomes related to systemic or functional imbalance, specifically looking at the incidence of Venous Thromboembolism (VTE) events. Observational data describes patterns related to VTE incidence, reporting different frequency patterns of events between the transdermal and oral administration routes. Certainty remains low as these findings rely mainly on large-scale observational evidence, where background factors may influence the results.

Key Studies & References

1. NICE Guideline NG23: Menopause: identification and management (Used for context on evidence synthesis and gaps)

Common questions about Evorel (FAQ)

---

Q: Does Evorel treat all symptoms of menopause?

Official regulatory guidance indicates that Evorel is used to address the main symptoms of oestrogen deficiency. This includes the relief of key vasomotor symptoms (like hot flushes and night sweats) and the prevention or treatment of osteoporosis. It may also provide relief for other menopausal symptoms, such as certain changes in sleep and emotional state.

---

Q: How quickly do people typically notice changes after starting Evorel?

According to guidance from authoritative medical bodies, the full therapeutic effect of Evorel is often seen developing over a period of three to six months. While some people may notice improvements sooner, this duration ensures the body has adequate time to stabilize hormone levels and fully respond to the therapy.

---

Q: Does Evorel interact with common over-the-counter pain relievers?

Direct interactions between the oestrogen component in Evorel and common over-the-counter pain relievers, such as ibuprofen, are not widely reported in regulatory documents. However, official information notes that nonsteroidal anti-inflammatory drugs (NSAIDs) carry certain risks (like cardiovascular events) which may be relevant when reviewing HRT use.

---

Q: What happens if I take antibiotics while using Evorel?

Regulatory sources focus on specific anti-infective medicines, such as rifampicin, which can induce liver enzymes and reduce the effectiveness of the oestrogen. General antibiotics are not typically listed as interacting with transdermal HRT.

---

Q: Is there a maximum time a person can stay on Evorel?

Official guidance states there is no arbitrary maximum time limit for using HRT. The treatment can be continued for as long as the benefits are judged to outweigh the risks, based on regular reviews with a healthcare provider. For individuals experiencing premature menopause, therapy is commonly advised until at least the average age of natural menopause (around 51).

---

Q: What does the term 'oestrogen-only' mean in the context of Evorel?

In the context of hormone therapy, 'oestrogen-only' means the product contains estradiol as the sole active ingredient, without the addition of a progestogen. Official use protocol mandates that women who still have a uterus must use a separate progestogen alongside oestrogen-only patches to help protect the uterine lining.

---

Q: Why do some people need to use different strengths of Evorel?

The decision to adjust the strength of Evorel is based on individual response, as the goal is to use the lowest effective dose. People may require a different strength if the initial dose is insufficient to fully relieve symptoms, if they are not absorbing the hormone effectively through the skin, or if original menopausal symptoms begin to return.

---

Q: What are the signs that Evorel might not be working as expected?

Signs that the Evorel patch may not be providing sufficient hormone support include the persistence or return of original menopausal symptoms, such as hot flushes or night sweats. Additionally, official safety information notes that unexpected or abnormal vaginal bleeding can sometimes be a sign of reduced efficacy, especially if the medicine is taken with a progestogen.

---

Q: Can I use lotions or creams on the area where the patch is applied?

Regulatory patient information specifies that the patch must be applied only to clean, dry, and cool skin. It is advised not to use any creams, moisturisers, oils, talc, or powders on the application site beforehand, as these products may prevent the patch from sticking properly and potentially interfere with the absorption of the hormone.

---

Q: Why do official documents specify that Evorel should not be applied to the breasts?

Official administration guidelines specifically state that the patch must not be placed on or near the breasts. This is a safety measure because the breast is a hormone-sensitive tissue, and direct application could lead to unwanted local absorption of the hormone or interfere with the risk profile associated with systemic hormone replacement therapy.

---

Q: Is it common for people to switch to Evorel from oral tablets?

Switching from oral hormone tablets to a transdermal patch like Evorel is a standard option described in clinical guidance. This transition may be recommended if a person experiences specific issues with the oral route, such as difficulty with absorption due to bowel disorders, or if the prescribed oral dose is insufficient to relieve their symptoms.

---

Q: If I stop using Evorel, will my symptoms return?

Official guidance notes that when treatment is discontinued, menopause symptoms are likely to return. To manage this transition, a healthcare professional may suggest gradually reducing the dose over time rather than stopping abruptly.

---

Q: Is feeling dizzy a known side effect of Evorel?

Yes, according to official adverse reaction lists, dizziness is listed as a Common side effect of Evorel, meaning it may affect between 1% and 10% of users. This side effect is categorized under nervous system disorders.

---

Q: Do Evorel patches cause changes in weight?

Official regulatory information reports that weight gain is a common adverse reaction for Evorel. General changes in weight (both loss and gain) are cited as potential systemic side effects of the medication.

---

Q: Can using Evorel affect mood or anxiety levels?

Official safety documentation indicates that Evorel can affect emotional state. Side effects such as irritability, mood swings, and feelings of sadness or emptiness are listed, which suggests a potential impact on mood and anxiety levels.

---

Q: Can certain foods or drinks interfere with how Evorel works?

Regulatory documents generally focus on drug-drug interactions. However, some scientific information suggests that compounds in certain foods, such as grapefruit juice, may potentially alter oestrogen levels, requiring awareness.

---

Q: Can Evorel be used by people who smoke?

Official safety warnings note that smoking is a significant risk factor for vascular conditions, such as venous thromboembolism (blood clots), which are serious adverse reactions associated with all systemic HRT. Therefore, patients who smoke must be aware of these risk factors and should discuss their risk status with a healthcare provider.

---

Q: Can the effectiveness of Evorel be reduced by heat or sweating?

According to the patient information leaflet, the Evorel patch is designed to remain effective during routine activities like showering, bathing, swimming, and exercise. However, official guidance advises that when sunbathing, the patch should be kept covered and out of direct sunlight.

---

Q: What if I forget what day to change my Evorel patch?

The official patient information advises that if a dose is forgotten, the patch should be changed as soon as the user remembers. The individual should then return to their original scheduled 'patch change' days. Forgetting a change may result in some unexpected vaginal bleeding or spotting.

---

Q: Are there any reported interactions with caffeine?

Official regulatory sources do not list caffeine as a drug that directly interacts with Evorel. However, certain guidance highlights that increased caffeine consumption may be a lifestyle factor that can trigger or worsen typical menopausal symptoms, which could then be mistaken for a reduction in the patch's effectiveness.

---

Q: Can the patch be worn while swimming or exercising?

Yes, the patch is designed to be worn while swimming, exercising, and playing sports. To maintain adhesion and function, patient guidance suggests avoiding the application of the patch under tight clothing or waistbands where friction may occur.

---

Q: Is Evorel approved for use in women under 40 experiencing premature menopause?

Yes, the treatment of Premature Ovarian Failure (POF) is listed as an indication for HRT in official guidance. Women who experience premature menopause (before age 40) are typically advised to use hormone replacement therapy at least until they reach the average age of natural menopause (around age 51).

---

Q: What is the purpose of the adhesive side of the patch?

The adhesive side of the patch serves the essential purpose of securing the system to the skin. This attachment is crucial because the medicine is delivered through the skin (transdermal route), which allows the continuous and consistent transfer of the active ingredient (estradiol) into the bloodstream.

---

Q: Are there specific warnings about using Evorel before surgery?

Yes. If surgery is planned, it is a regulatory requirement to inform the surgeon and healthcare provider. To reduce the risk of blood clots (venous thromboembolism), which is associated with HRT, individuals may be advised to temporarily stop using the patch approximately four to six weeks before the procedure.

---

Q: Is there a typical time of day recommended for applying a new patch?

Official instructions emphasize applying the patch immediately after opening the protective sachet to clean, dry, and cool skin. There is no specific time of day (e.g., morning or evening) that is mandated for application, only the required frequency of changing the patch twice weekly.

How to Store and Dispose of Evorel Patches

Official regulatory guidelines dictate specific conditions for storing and disposing of Evorel (estradiol transdermal system) patches.

---

Storage Requirements

Patches must be stored at or below 25 C and should not be stored above this temperature. To maintain product stability, the patch must remain in its original sealed sachet and outer carton and be applied immediately after opening the sachet. All patches must be kept out of the sight and reach of children.

---

Disposal Instructions

To dispose of a used patch, fold it in half so the sticky side adheres to itself, containing the residual medicine. The folded patch should then be discarded with household waste. It is officially mandated that used patches must not be flushed down the toilet or disposed of in wastewater. Unused or expired patches should be returned to a community drug take-back program when available.